Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: avadel.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/23/2025 | $20.00 | Buy → Neutral | H.C. Wainwright |
| 9/3/2025 | $16.00 | Equal Weight | Wells Fargo |
| 7/18/2025 | $22.00 | Buy | H.C. Wainwright |
| 2/11/2025 | $12.00 | Buy | Deutsche Bank |
| 6/12/2024 | $27.00 | Buy | Rodman & Renshaw |
| 3/5/2024 | $27.00 → $29.00 | Outperform | Oppenheimer |
| 3/5/2024 | $21.00 → $25.00 | Buy | H.C. Wainwright |
| 3/5/2024 | $20.00 → $22.00 | Buy | Needham |
| 2/6/2024 | $21.00 | Buy | UBS |
| 11/30/2022 | $6.50 → $11.00 | Hold → Buy | Jefferies |
DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
SCHEDULE 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
S-8 - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
S-3ASR - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright downgraded Avadel Pharmaceuticals from Buy to Neutral and set a new price target of $20.00
Wells Fargo initiated coverage of Avadel Pharmaceuticals with a rating of Equal Weight and set a new price target of $16.00
H.C. Wainwright resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00
Deutsche Bank initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously
H.C. Wainwright reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $21.00 previously
Needham reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $20.00 previously
UBS initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $21.00
Jefferies upgraded Avadel Pharmaceuticals from Hold to Buy and set a new price target of $11.00 from $6.50 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
3 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
Fastest customizable press release news feed in the world
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES — Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)— Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton— Expected to be Immediately Accretive and Enhance Profitability Upon Closing— Positions the Combined Organization to Accelerate Inn
DUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. ("Jazz"). Under the primary terms of the settlement agreement, Avadel and Jazz will dismiss their respective lawsuits with prejudice. Furthermore, Jazz agrees to grant Avadel the following: A perpetual, worldwide license to any past, present, or future patents that could be asserted against LUMRYZ for any and all present and future indications, strengths, conditions of use, dosages, doses, dosage forms, and presentations.Jazz will make a p
DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the
A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel Pharmaceuticals are celebrating five years of collaboration and dedicated support for early-career sleep researchers and future sleep physicians. In 2021, Avadel became the Young Investigator Research Forum's (YIRF) inaugural corporate sponsor. Thanks to support from Avadel and other companies, YIRF has empowered dozens of trainees and junior faculty in sleep and circadian science, providing them with mentorship, grant-writing training, and networking opportunities that have
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the
– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16 posters at World Sleep 2025, taking place Se
– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 with pivotal PK trial planned for second half 2026 – – XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales – DUBLIN and REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. ("XWPharma") toget
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference: Fireside chat on Friday, September 5 at 11:00 a.m. ET.Morgan Stanley 23rd Annual Global Healthcare Conference: Fireside chat on Tuesday, September 9 at 1:05 p.m. ET.H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Wednesday, September 10 at 9:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Invest
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to eight (8) new employees to purchase 60,400 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.
Live Leadership Updates
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez as Chief Operating Officer. In this newly created role, Ms. Rodriguez will lead all aspects of the Company's commercial strategy, structure, organization, and related operations, including supply chain. "Susan is an accomplished biopharma executive with a track record of strategic leadership and excellence in commercializing innovative medicines," said Gregory J. Divis, Chief Executive Officer of Avadel. "Her expertise will be invaluable at this critical
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets. "We're delighted to welcome Kevin to Avadel – he's a great addition to our team with the deep experience to help us drive success at this important time," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Kevin's expertise and proven track record in build
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations. "We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improvin
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. "We are pleased to welcome Brandi to the Avadel team as our Senior Vice President, Corporate Affairs as we continue to advance once-at-bedtime FT218 for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy," said Greg Divis, Chief Executive Officer of Avadel. "Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the compa
DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer. "Doug is an outstanding addition to the Avadel leadership team given his extensive experience in the biopharmaceutical industry leading R&D, clinical development and medical affairs teams in the neuroscience field," said Greg Divis, Chief Executive Officer of Avadel. "His expertise in pre- and post-approval clinical development, data generation and regulatory strategy will support all aspects of FT218 as we look to bring this important treatment t
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs, effective immediately. In this role her responsibilities will include overseeing all medical and clinical affairs activities, including the company’s lead program, once-nightly FT218. “We are pleased to further strengthen our team with the appointment of Dr. Gudeman. Her broad med
This live feed shows all institutional transactions in real time.
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
Live finance-specific insights
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES — Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)— Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton— Expected to be Immediately Accretive and Enhance Profitability Upon Closing— Positions the Combined Organization to Accelerate Inn
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- Raises 2025 full year revenue guidance to $265 - $275 million -- -- Received Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the treatment of Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH by end of 2025 -- -- Avadel management to host conference call today at 8:30 a.m.
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 7, 2025, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 -- -- Raises 2025 guidance; expects to generate $255 - $265 million in net product revenue and cash flow of $30 - $40 million, driven by 3,400 - 3,600 patients on LUMRYZ by year end -- -- Federal Circuit ruled in Avadel's favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) -- -- On track to complete enrollment in
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here a
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter -- -- LUMRYZ net product revenue of $240 – $260 million in 2025, representing 50% year-over-year growth at the midpoint -- -- Management to host a conference call today at 4:30 p.m. ET -- DUBLIN, Ireland, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a busines
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised